177 related articles for article (PubMed ID: 1667669)
1. Pharmacokinetics and metabolism of HOE 077. Preclinical studies.
Kellner HM; Volz M; Badder E; Kürzel GU; Eckert HG
J Hepatol; 1991; 13 Suppl 3():S48-61; discussion S62. PubMed ID: 1667669
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man.
Eckert HG; Badian MJ; Gantz D; Kellner HM; Volz M
Arzneimittelforschung; 1984; 34(10B):1435-47. PubMed ID: 6097271
[TBL] [Abstract][Full Text] [Related]
3. Absorption, distribution, metabolism and excretion of a new, 14C-labelled oxazolidinone MAO-A inhibitor in rat and dog.
Naitoh T; Mishima M; Kawaguchi S; Matsui K; Andoh T; Kagei K; Kakiki M; Yuzuriha T; Horie T
Xenobiotica; 1997 Oct; 27(10):1053-70. PubMed ID: 9364742
[TBL] [Abstract][Full Text] [Related]
4. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs.
Brodie RR; Mayo BC; Chasseaud LF; Hawkins DR
Arzneimittelforschung; 1977; 27(3):593-8. PubMed ID: 577426
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of labetalol by animals and man.
Martin LE; Hopkins R; Bland R
Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):695-710. PubMed ID: 990152
[TBL] [Abstract][Full Text] [Related]
6. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of inhibitors of prolyl 4-hydroxylase in CCl4-induced fibrosis of the liver in rats.
Bickel M; Baader E; Brocks DG; Engelbart K; Günzler V; Schmidts HL; Vogel GH
J Hepatol; 1991; 13 Suppl 3():S26-33; discussion S34. PubMed ID: 1667666
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of the new antihypertensive agent pinacidil in rat, dog and man.
Eilertsen E; Magnussen MP; Petersen HJ; Rastrup-Andersen N; Sørensen H; Arrigoni-Martelli E
Xenobiotica; 1982 Mar; 12(3):187-96. PubMed ID: 7113255
[TBL] [Abstract][Full Text] [Related]
9. [Biochemical studies with oxitropium bromide. 1. Pharmacokinetics and metabolism in the rat and dog].
Wahl D; Förster HJ; Pook KH; Richter I
Arzneimittelforschung; 1985; 35(1A):255-65. PubMed ID: 4039166
[TBL] [Abstract][Full Text] [Related]
10. Absorption, distribution, metabolism, and excretion of [¹⁴C]GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway via pyridine ring opening.
Yue Q; Chen YH; Mulder T; Deese A; Takahashi R; Rudewicz PJ; Reynolds M; Solon E; Hop CE; Wong H; Khojasteh SC
Drug Metab Dispos; 2011 Jun; 39(6):952-65. PubMed ID: 21363998
[TBL] [Abstract][Full Text] [Related]
11. The metabolism of the anti-inflammatory drug eterylate in rat, dog and man.
Wood SG; John BA; Chasseaud LF; Johnstone I; Biggs SR; Hawkins DR; Priego JG; Darragh A; Lambe RF
Xenobiotica; 1983 Dec; 13(12):731-42. PubMed ID: 6144210
[TBL] [Abstract][Full Text] [Related]
12. Effects of the prolyl 4-hydroxylase proinhibitor HOE 077 on human and rat hepatocytes in primary culture.
Clément B; Chesné C; Satie AP; Guillouzo A
J Hepatol; 1991; 13 Suppl 3():S41-7. PubMed ID: 1667668
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of nitrendipine. I. Absorption, plasma concentrations, and excretion after single administration of [14C]nitrendipine to rats and dogs.
Krause HP; Ahr HJ; Beermann D; Siefert HM; Suwelack D; Weber H
Arzneimittelforschung; 1988 Nov; 38(11):1593-9. PubMed ID: 3214442
[TBL] [Abstract][Full Text] [Related]
14. Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog.
Filer CW; Ramji JV; Allen GD; Brown TA; Fowles SE; Hollis FJ; Mort EE
Xenobiotica; 1995 May; 25(5):477-90. PubMed ID: 7571721
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
Mukai H; Sugimoto T; Ago M; Morino A
Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tissue distribution of ketanserin in rat, rabbit and dog.
Michiels M; Monbaliu J; Meuldermans W; Hendriks R; Geerts R; Woestenborghs R; Heykants J
Arzneimittelforschung; 1988 Jun; 38(6):775-84. PubMed ID: 3178917
[TBL] [Abstract][Full Text] [Related]
17. Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism.
Maurer G; Schreier E; Delaborde S; Nufer R; Shukla AP
Eur J Drug Metab Pharmacokinet; 1983; 8(1):51-62. PubMed ID: 6861794
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetics and biotransformation of the analgesic flupirtine in the rat and dog].
Obermeier K; Niebch G; Thiemer K
Arzneimittelforschung; 1985; 35(1):60-7. PubMed ID: 4039153
[TBL] [Abstract][Full Text] [Related]
19. Prolyl 4-hydroxylase inhibitor (HOE 077) inhibits pig serum-induced rat liver fibrosis by preventing stellate cell activation.
Matsumura Y; Sakaida I; Uchida K; Kimura T; Ishihara T; Okita K
J Hepatol; 1997 Jul; 27(1):185-92. PubMed ID: 9252094
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.
Hong H; Su H; Sun H; Allentoff A; Ekhato IV; Chando T; Caceres-Cortes J; Roongta V; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2010 Jul; 38(7):1189-201. PubMed ID: 20363952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
